A nurse is assisting with the care of a client who has severe preeclampsia and is receiving magnesium sulfate IV at 2 g/hr. Which of the following findings indicates that it is safe for the nurse to continue the infusion?

Choice A rationale:

The nurse should schedule a 3-hour oral glucose tolerance test (OGTT) for the client because the blood glucose levels taken 1 hour following a meal are higher than the expected range for gestational diabetes. This test will help to diagnose and assess the client's glucose tolerance and determine if there is gestational diabetes or any other potential glucose regulation issues.

Choice B rationale:

Increasing carbohydrates to 65% of daily nutritional intake is not the appropriate action in this situation. It may lead to further elevation of blood glucose levels, which can be detrimental for a client with gestational diabetes. The goal is to manage blood glucose levels and prevent complications, so recommending a higher carbohydrate intake would be counterproductive.

Choice C rationale:

Obtaining an HbA1c (glycated hemoglobin) is not the most suitable action in this scenario. HbA1c provides an average of the blood glucose levels over the past few months, which is more helpful for diagnosing and monitoring chronic diabetes, rather than gestational diabetes, which is temporary and occurs during pregnancy. An OGTT is a more appropriate test for gestational diabetes assessment.

Choice D rationale:

Reinforcing instruction about insulin administration is not warranted at this point since there is no information indicating that the client is currently on insulin therapy. Additionally, using insulin as the first step in the management of gestational diabetes is not common practice. Lifestyle modifications, dietary changes, and other measures are usually attempted first.

Choice D rationale:

The nurse should state, "The purpose of this medication is to boost fetal lung maturity.”. The rationale behind this choice is that betamethasone is a corticosteroid medication commonly administered to women at risk of preterm delivery between 24 and 34 weeks of gestation. Its primary goal is to accelerate fetal lung maturation by promoting the production of surfactant, a substance that coats the lungs and prevents their collapse. By enhancing lung development, the medication helps reduce the risk of respiratory distress syndrome and other respiratory complications that premature infants might face. It does not directly impact fetal heart rate (Choice A), halt cervical dilation (Choice B), or stop preterm labor contractions (Choice C).

Choice A rationale:

The nurse should not state, "The purpose of this medication is to increase the fetal heart rate.”. Betamethasone does not affect the fetal heart rate, as it is primarily used to enhance lung maturity, as mentioned earlier. The incorrect statement may lead to confusion and misunderstanding of the medication's intended purpose.

Choice B rationale:

The nurse should not state, "The purpose of this medication is to halt cervical dilation.”. Betamethasone does not stop or halt cervical dilation. Its main action is on the fetal lungs to promote surfactant production. Cervical dilation is a natural process that occurs during labor and is not influenced by this medication.

Choice C rationale:

The nurse should not state, "The purpose of this medication is to stop preterm labor contractions.”. Betamethasone is not used to stop or prevent preterm labor contractions directly. Instead, its focus is on improving fetal lung maturity to enhance the baby's respiratory function once born prematurely.